**4.5 Uterine weight**

We recorded the same result in uterine weight also where *Cannabis* treatment profoundly (*P* < 0.01) decreased uterine weight as compared to control. However, the difference in uterine weight between two experimental groups was not significant (*P* > 0.05).

### **4.6 Total serum cholesterol**

Serum cholesterol also showed significant dose dependent decrease (*P* < 0.01) in serum cholesterol level upon *Cannabis* treatment being lowest in 12 mg/100 g of body weight group as compared to control. However, the difference between two experimental groups was statistically non-significant (*P* > 0.05).

#### **4.7 3β HSD enzyme activity in ovary**

Significant decrease in 3β HSD enzyme activity (*P* < 0.01) was noted in a dose dependent manner in *Cannabis* treated ovaries as compared to control. However, the difference between two experimental groups was statistically non-significant (*P* > 0.05).

#### **4.8 17β HSD enzyme activity in ovary**

Significant decrease (*P* < 0.01) in 17β HSD enzyme activity was noted in *Cannabis* treated ovaries in comparison to control. The difference in decreased activity between two experimental groups was also statistically significant (*P* < 0.05).

#### **4.9 SOD activity in ovary**

Significant increase in SOD activity was noted in *Cannabis* treated groups in dose dependent manner being significantly high (*P* < 0.01) in both the groups of 6 mg/100 g of body weight and 12 mg/100 g of body weight as compared to control. The level was highest in the latter group in comparison to 6 mg/100 g of body weight (*P* < 0.05).

#### **4.10 Catalase activity in ovary**

Significant increase in catalase activity was noted in *Cannabis* treated groups in dose-dependent manner (*P* < 0.01) as compared to control. But, among the treated groups the level was not significant (*P* > 0.05).

#### **4.11 Malondialdehyde level in ovary**

Significant decrease in ovarian malondialdehyde levels were noted in a dose dependent manner following *Cannabis* treatment being lowest in 12 mg/100 g of body weight dose (*P* < 0.01). The level in the 6 mg/100 g of body weight dose was intermediate with significantly lower level (*P* < 0.05) than control. Among the treated groups, group 3 showed least level of MDA activity (*P* < 0.05).

#### **4.12 GPx level in ovary**

Glutathione peroxide (GPx) level was found to be significantly high (*P* < 0.01) in both the treatment groups when compared to control. Among 6 mg/100 g body

weight and 12 mg/100 g body weight groups, the latter showed significantly high level (*P* < 0.01).
